OmniAb SPAC Presentation Deck

ZIMBERELIMAB APPROVED THE FIRST APPROVED OMNIRAT-DERIVED ANTIBODY ● gloria • On August 30, 2021, zimberelimab (GLS-010), an OmniAb-derived fully human anti-PD-1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin's lymphoma Marks the first approval of an OmniAb-derived mAb - BIOSCIENCES In 2015, GloriaBio contracted with WuXi Biologics to discover and develop zimberelimab in China using OmniRat Zimberelimab entered clinic in March 2017, and NDA was submitted to China NMPA in February 2020 GloriaBio is also investigating zimberelimab in advanced solid tumors, and was granted Breakthrough Therapy designation for the treatment of patients with recurrent/metastatic cervical cancer in March 2021 Zimberelimab is being developed by Arcus Biosciences (in collaboration with Gilead) in North America, Europe, Japan and certain other territories through a 2017 agreement 33 OmniAb

View entire presentation